Antibody therapy developer Harbour BioMed has completed a series B round backed by China Life and existing investor Legend Capital.
China-based cancer and inflammatory disease therapy developer Harbour BioMed closed an $85m series B round on Sunday that included insurance firm China Life, which invested through China Life Private Equity Investment Company.
Singaporean sovereign wealth fund GIC led the round, which included Legend Capital, the venture capital firm set up by conglomerate Legend Holdings, as well as the Singaporean state-owned Vertex Ventures and fellow VC firm AdvanTech Capital.
Harbour is working on immuno-oncology and inflammatory disease medicines. The series B…